ProPhase Labs (PRPH) Board Declares Share Repurchase Program
ProPhase Labs (NASDAQ:PRPH) declared that its board has authorized a stock buyback plan, which allows the company to buyback 4,000,000 outstanding shares on Tuesday, August 15th, EventVestor reports. This buyback authorization allows the company to reacquire shares of its stock through a tender offer. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.
ProPhase Labs (NASDAQ:PRPH) traded up 5.63% during trading on Wednesday, reaching $2.25. The company’s stock had a trading volume of 37,929 shares. ProPhase Labs has a 52 week low of $1.70 and a 52 week high of $2.45. The firm has a market cap of $38.60 million, a P/E ratio of 0.90 and a beta of 0.07. The stock’s 50 day moving average is $2.06 and its 200-day moving average is $2.03.
ProPhase Labs (NASDAQ:PRPH) last released its quarterly earnings results on Friday, August 11th. The company reported ($0.09) EPS for the quarter. The business had revenue of $1.91 million for the quarter. ProPhase Labs had a return on equity of 71.53% and a net margin of 270.98%.
ProPhase Labs Company Profile
ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.
Receive News & Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.